Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00465907|
Recruitment Status : Unknown
Verified December 2008 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Recruitment status was: Active, not recruiting
First Posted : April 25, 2007
Last Update Posted : December 17, 2008
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: Paclitaxel, Carboplatin, Irinotecan||Phase 2|
Lung cancer is the leading cancer death in many countries of the world including Singapore. Non-small cell lung cancer (NSCLC) consists of 80-85% of lung cancers, and is a major health problem. The main etiology of lung cancer is well recognized and established to be cigarette smoking which accounts for up to 80% of the cases in the western countries. Due to success of anti-smoking campaig, we anticipate to see less smoking related lung cancer and more non-smoking related lung cancer which is rising rapidly. For eg, currently in Singapore, smoking only accounts for 50-60% of all lung cancers, this is particularly true in female patients, as smoking occured in 30-40% of female lung cancer patients only.
It is unclear if there is any significant difference in the fundamental biology between smoking and non-smoking related lung cancers, particularly in areas of natural course of disease, genetic changes of tumor cells, clinical presentation, response to treatment or survival. These are potential aspects for further investigation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Weekly Paclitaxel, Carboplatin and Irinotecan in Patients With Advanced Non-Small Cell Lung Cancer Nad Malignant Plerual Effusion|
|Study Start Date :||May 2003|
|Estimated Primary Completion Date :||November 2008|
|Estimated Study Completion Date :||December 2009|
Drug: Paclitaxel, Carboplatin, Irinotecan
- To evaluate the efficacy and toxicity of the weekly combination chemotherapy of paclitaxel, carboplatin and irinotecan in Stage IIIB and IV NSCLC patients with malignant pleural effusion [ Time Frame: 3 years ]
- To determine the pharmacokinetics and pharmacodynamics of paclitaxel and irinotecan in the blood and pleural effusion. [ Time Frame: 3 years ]
- To compare the gene expression pattern of non-small cell lung cancer from cigarette-smoking, passive smoking and no tobacco exposure patients before and after chemotherapy. [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00465907
|Johns Hopkins Singapore International Medical Center|
|Singapore, Singapore, 308433|
|Principal Investigator:||Alex Chang, MD||Johns Hopkins SIngapore International Medical Center|